We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03721705
Recruitment Status : Completed
First Posted : October 26, 2018
Results First Posted : April 19, 2022
Last Update Posted : May 11, 2022
Sponsor:
Collaborators:
Navitas Clinical Research, Inc
ClinEdge, LLC
Information provided by (Responsible Party):
Renew Research, LLC

Brief Summary:
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends to examine the efficacy and safety of RenewTM NCP-5 therapy in the treatment of Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type. Subjects will be prospectively randomized to treatment or sham (in a 1:1 ratio) using stratification for Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type, and Cardiovascular Risk (CVR) score at multiple sites. Subjects, ages 55-85, will be consented for 13 months and will receive thirty-five 60-minute RenewTM NCP-5 treatment sessions during a 7-to-12-week initial treatment period, and then transition to a lower frequency maintenance period (twice a week) for a total treatment period of 24 weeks.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Cognitive Dysfunction Mild Cognitive Impairment Mild Dementia Cognitive Decline Dementia, Alzheimer Type Device: Renew NCP-5 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 190 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized to either the treatment group or the sham group.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type
Actual Study Start Date : November 12, 2018
Actual Primary Completion Date : March 23, 2021
Actual Study Completion Date : March 23, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Arm
The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
Device: Renew NCP-5
Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.

Sham Comparator: Sham Arm
The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
Device: Renew NCP-5
Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.




Primary Outcome Measures :
  1. Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks. [ Time Frame: 24 weeks ]
    The vADAS-cog assessment includes 17 subscale scores. The total score is the sum of all scaled scored from 0-120. The higher values represent more cognitive impairment. The change in vADAS-cog scores from baseline at the timepoints of 12, 18, and 24 weeks is averaged together for each patient. The primary outcome measure is the average of those values for all patients in a group.


Secondary Outcome Measures :
  1. Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA. [ Time Frame: 24 weeks ]
  2. Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA. [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be 55-85 years of age at the time of signing the informed consent
  2. Be able to provide consent or have legally authorized representative/caregiver who can provide consent
  3. Be able to read and write in English or Spanish
  4. Have a clinical diagnosis consistent with 2011 National Institute of Aging - Alzheimer's Association (NIA-AA) "core clinical criteria" guidelines for: (i) The diagnosis of dementia due to Alzheimer's disease or (ii) The diagnosis of mild cognitive impairment due to Alzheimer's disease:

    • Montreal Cognitive Assessment (MOCA) score of greater than or equal to 11
    • All required checkboxes within the study checklist for "The diagnosis of probable AD dementia" must be "yes" or
    • All required checkboxes within the study checklist for "The diagnosis of mild cognitive impairment due to Alzheimer's disease" must be "yes"
  5. Stable medications for past 30 days and plan to remain on stable medications for the first 24 weeks of study participation for treatment of chronic conditions.
  6. Subject should have a caregiver, study partner or companion (which can be a domestic party) and may conduct the assessment over the phone if they don't accompany the participant).
  7. Must have the potential to improve by at least 2 points or more in the Vascular Dementia Assessment Scale cognitive subscale (vADAS-COG)

Exclusion Criteria:

  1. Unwilling or unable to participate in study procedures
  2. Weight >297 lbs. or >135 kg at screening
  3. Major confounding neurodegenerative or psychiatric disorder unrelated to the condition under study, including:

    1. History of clinically-evident stroke
    2. Current uncontrolled epileptic seizures or epilepsy
    3. Multiple Sclerosis or Parkinson's Disease
    4. Current clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria or significant psychiatric symptoms (e.g., hallucinations) that could impair the completion of the study
  4. Anyone with active or history of cerebral hemorrhage including subdural & subarachnoid or cerebral aneurysm
  5. Evidence of any of the following (based on Section 4.1.1(D) of the 2011 NIA-AA guidelines on The diagnosis of dementia due to Alzheimer's disease):

    1. Substantial concomitant cerebrovascular disease, defined by a history of a stroke temporally related to the onset or worsening of cognitive impairment; or the presence of multiple or extensive infarcts or severe white matter hyperintensity burden
    2. Core features of Dementia with Lewy bodies other than dementia itself
    3. Prominent features of behavioral variant frontotemporal dementia
    4. Prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive aphasia
    5. Evidence for another concurrent, active neurological disease, non-neurological medical comorbidity or use of medication that could have a substantial effect on cognition
  6. In the opinion of the investigator, any current clinically-significant systemic illness or medical condition that is likely to result in deterioration of the subject's condition, affect the subject's safety during the study, or to be incompatible with performance of the study procedures, including:

    1. History of head trauma with a diagnosis of moderate to severe traumatic brain injury
    2. Known current substantially elevated intracranial pressure
    3. Known current significant sleep deprivation
    4. Known history (within five years) or current significant drug abuse or alcoholism
  7. Any contraindication for MRI such as insulin pumps or pacemakers, including dual chamber pacemakers where atrial pacing may interfere with RenewTM NCP-5 inflation timing sequence
  8. Hypotension as defined as <80/50 blood pressure at the time of screening
  9. Ongoing uncontrolled severe hypertension (≥ 180 mmHg systolic or ≥ 110 mmHg diastolic
  10. Heart rates < 35 or >125 beats per minute (BPM) at screening
  11. Current uncontrolled arrhythmia. Controlled arrhythmia should have beat-to-beat, cycle-length variability less than ±25% at rest.
  12. Current congestive heart failure
  13. Cardiac catheterization within two weeks, any surgical intervention within six weeks before RenewTM NCP-5 treatment or a hip or knee replacement within 3 months as long as rehab is complete and symptoms have resolved.
  14. Known presence of abdominal aortic aneurysm
  15. Existing aortic insufficiency grade II or higher (regurgitation can prevent diastolic augmentation)
  16. Current or past venous thrombosis or thromboembolism
  17. Current limiting peripheral vascular disease with history strongly suggestive of lower extremity ischemia or claudication, arterial occlusive disease (aortoiliac, ileofemoral, or femoral popliteal)
  18. Demonstrable deficiency in sensation in lower extremities as a result of diabetes or other medical condition
  19. Current bleeding disorders.
  20. Current use of major anti-coagulation therapy (such as Heparin therapy or Coumadin® therapy) with International Normalized Ratio (INR) > 1.5
  21. Current severe pulmonary disease that prevents the subject from lying supine
  22. Presence of local infection, vasculitis, burn, open wound, or bone fracture on any limb which would prevent the ability to perform the RenewTM NCP-5 treatment
  23. Current use of medications that in the investigator's judgement are incompatible with the study goals
  24. Significant changes in existing medical plans for treatment of cognitive impairment or dementia in last three months and/or or planned changes during the trial
  25. Presence of any of the contraindications for using the RenewTM NCP-5 device
  26. Athletic injuries, including Charley horses, pulled muscles and/or edematous muscles; necrotizing cellulitis in the past 30 days which would prevent the ability to perform the RenewTM NCP-5 treatment (evaluate and treat prior to RenewTM NCP-5 treatment)
  27. Unwilling or unable to maintain stable exercise regimen throughout the trial
  28. Participation in any clinical drug trial 30 days or five half-lives, whichever is longer, prior to screening visit
  29. Use of any device to increase cerebral blood flow in the past 30 days.
  30. History of claustrophobia.
  31. Subject unable to lay supine for 90 minutes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03721705


Locations
Layout table for location information
United States, Arizona
Xenoscience
Phoenix, Arizona, United States, 85004
United States, California
Irvine Clinical Research
Irvine, California, United States, 92614
United States, Florida
Charter Research
Lady Lake, Florida, United States, 32159
Miami Dade Medical Research Institute
Miami, Florida, United States, 33176
United States, Georgia
iResearch Atlanta
Atlanta, Georgia, United States, 30030
iResearch Savannah
Savannah, Georgia, United States, 31405
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Louisiana
Cardiovascular Advantages, LLC
Baton Rouge, Louisiana, United States, 70806
United States, Ohio
Neuro-Behavioral Clinical Research
Canton, Ohio, United States, 44718
United States, Washington
Northwest Clinical Research Center
Bellevue, Washington, United States, 98007
Ireland
St. James's Hospital
Dublin, Ireland
Singapore
National University Hospital
Singapore, Singapore
Sponsors and Collaborators
Renew Research, LLC
Navitas Clinical Research, Inc
ClinEdge, LLC
Investigators
Layout table for investigator information
Study Director: Billy Tally Stage 2 Innovations
  Study Documents (Full-Text)

Documents provided by Renew Research, LLC:
Study Protocol  [PDF] December 30, 2020
Statistical Analysis Plan  [PDF] December 3, 2020
Informed Consent Form  [PDF] January 13, 2020

Layout table for additonal information
Responsible Party: Renew Research, LLC
ClinicalTrials.gov Identifier: NCT03721705    
Other Study ID Numbers: RenewTM NCP-5-1001
First Posted: October 26, 2018    Key Record Dates
Results First Posted: April 19, 2022
Last Update Posted: May 11, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Cognitive Dysfunction
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders